Insuman Comb 50

Insulin human, the active ingredient in Insuman Comb 50, is a insulin presented as a 50 U/mL premixed insulin injection for subcutaneous use. It treats diabetes mellitus in both type 1 and type 2 patients.\n\nGNH India supplies Insuman Comb 50 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance.

Insuman Comb 50 is a premixed insulin indicated for diabetes mellitus management, providing both basal and prandial glucose control.\n\n- Type 1 diabetes mellitus: supplies both rapid‑acting and intermediate‑acting insulin in a fixed 1:1 ratio to simplify multiple daily injections and achieve basal‑prandial control.\n- Type 2 diabetes mellitus: used when oral hypoglycemics no longer maintain target glucose, providing combined basal and mealtime insulin in a single injection.

The following adverse reactions have been reported with Insuman Comb 50.\n\nCommon Side Effects:\n- Hypoglycemia: episodes of low blood glucose that may cause shakiness, sweating, confusion or loss of consciousness if untreated.\n- Injection site reactions: redness, swelling, itching or bruising at the subcutaneous injection site.\n- Weight gain: gradual increase in body weight associated with improved glycemic control and insulin’s anabolic effects.\n- Lipodystrophy: localized thickening or atrophy of subcutaneous fat tissue due to repeated injections.\n\nSerious or Rare Side Effects:\n- Allergic reactions: urticaria, angioedema or anaphylactic shock requiring immediate medical attention.\n- Severe hypoglycemia: profound low glucose levels leading to seizures, coma or loss of consciousness.\n- Edema: peripheral or generalized fluid retention that may be accompanied by shortness of breath.

When using Insuman Comb 50, consider the following precautions.\n\n- Dose individualization: titrate based on blood glucose monitoring and clinical response.\n- Hypoglycemia risk: educate patients on recognizing and treating low glucose.\n- Renal impairment: monitor closely as insulin clearance may be reduced.\n- Pregnancy and lactation: use only if benefits outweigh potential risks; consult healthcare provider.\n- Concomitant medications: assess for agents that may potentiate hypoglycemia (e.g., sulfonylureas).\n- Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insuman Comb 50 may interact with other medicines.\n\nMajor Interactions (Avoid):\n- Beta‑blockers: may mask hypoglycemia symptoms.\n- MAO inhibitors: can potentiate insulin’s glucose‑lowering effect.\n- High‑dose corticosteroids: may cause significant hyperglycemia requiring dose adjustment.\n\nModerate Interactions (Monitor Closely):\n- Oral antidiabetic agents (e.g., sulfonylureas, meglitinides): increased risk of hypoglycemia.\n- Thiazide diuretics: may raise blood glucose levels.\n- ACE inhibitors: may enhance insulin sensitivity, requiring monitoring.